The modified Glasgow prognostic score in patients undergoing surgery for bone and soft tissue sarcoma

Morhij, Rossel; Mahendra, Ashish; Jane, MJ; McMillan, Donald C.

doi:10.1016/j.bjps.2017.01.016

Cited by 16 publications

(22 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This exceptional study was excluded because the data cannot be adequately transformed. Finally, 12 eligible studies with 2695 patients were included in this meta-analysis [30][31][32][33][34][35][36][37][38][39][40][41]. There is no disagreement among the two investigators during the data extraction process.…”

Section: Searchmentioning

confidence: 99%

“…The main features of the 12 included studies are summarized in Table 1. In short, four studies were conducted in Europe (1 in UK and 3 in Denmark) [30,32,35,40], while the other eight were in Asia (6 in China and 2 in Japan) [31,33,34,[36][37][38][39][40][41]. The sample size ranged from 83 to 888, while the follow-up time ranged from 20.3 months to 19 years.…”

Section: The Characteristics Of the Included Studiesmentioning

confidence: 99%

“…All the 12 included studies were retrospectively designed. Five studies focused on bone sarcoma patients [30,31,33,34,41], another five focused on soft tissue sarcoma patients [35][36][37][38][39], and the other two focused on both bone and soft tissue sarcoma patients [32,40]. Five of the 12 included studies declared that patients with medical conditions known to affect systemic inflammation status were excluded [31,33,34,36,38].…”

Section: The Characteristics Of the Included Studiesmentioning

confidence: 99%

“…Eleven studies investigated the prognostic value of GPS for sarcoma patients. Seven of them reported the prognostic role of GPS for OS [30,31,33,34,36,38,39], four of them reported the prognostic role of GPS for DSS [30,32,35,40], and another four reported the prognostic role of GPS for DFS [32,[36][37][38]. Nine of the eleven studies evaluated traditional GPS, one [32] evaluated mGPS (modified GPS), two [36,37] evaluated Hs-mGPS (high sensitive modified GPS), and the other one [38] evaluated both traditional GPS and mGPS.…”

Section: The Characteristics Of the Included Studiesmentioning

confidence: 99%

“…The prognostic significance of GPS and CAR has also been investigated in sarcoma patients, and controversial results have also been reported [30][31][32][33][34][35][36][37][38][39][40][41][42]. To our knowledge, no system review or meta-analysis has been conducted on this subject for sarcoma.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

The Prognostic Role of Glasgow Prognostic Score and C-reactive Protein to Albumin Ratio for Sarcoma: A System Review and Meta-Analysis

et al. 2020

View full text Add to dashboard Cite

Backgrounds. Both pretreatment serum CRP (C-reactive protein) level and ALB (albumin) level have been found to be predictive of survival for multiple malignancies including sarcoma. Since both of the GPS (Glasgow prognostic score) and CAR (C-reactive protein to albumin ratio) are based on the combination of CRP and ALB, we conducted a meta-analysis to evaluate the prognostic role of these two parameters for sarcoma patients. Methods. A detailed literature search was conducted in MEDLINE, Embase, and Cochrane Library for relevant research publications written in English. Patients' clinical characteristics, outcomes of overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) were extracted. Pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were combined to evaluate the prognostic role of GPS or CAR. Results. Twelve articles containing 2695 patients were identified as eligible studies. The results showed that an elevated GPS was significantly correlated with poor OS (HR = 2:42; 95% CI: 1.98-2.94; p < 0:001; fixed-effects model), DSS (HR = 2:28; 95% CI: 1.75-2.97; p < 0:001; fixed-effects model), and DFS (HR = 2:05; 95% CI: 1.62-2.60; p < 0:001; fixed-effects model). A higher CAR also was shown to be significantly correlated with poor OS (HR = 2:23; 95% CI: 1.70-2.92; p < 0:001; fixed-effects model) and DFS (HR = 1:81; 95% CI: 1.7-2.58; p = 0:001; fixed-effects model). Conclusion. An elevated GPS is predictive of poor survival in patients with sarcomas and is promising to be used as a factor for risk stratification. A higher CAR value is also predictive of poor survival; however, the optimal CAR cut-off value is still to be determined.

show abstract

Section: Searchmentioning

confidence: 99%

Section: The Characteristics Of the Included Studiesmentioning

confidence: 99%

Section: The Characteristics Of the Included Studiesmentioning

confidence: 99%

Section: The Characteristics Of the Included Studiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The Prognostic Role of Glasgow Prognostic Score and C-reactive Protein to Albumin Ratio for Sarcoma: A System Review and Meta-Analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

Analysis of prognostic factors in soft tissue sarcoma: Cancer registry from a single tertiary hospital in Indonesia. A retrospective cohort study

Mahyudin

Edward

Basuki

et al. 2020

Annals of Medicine and Surgery

View full text Add to dashboard Cite

Background Soft tissue sarcoma is one cause of mortality in adult malignancies. This tumor is rare, persistent, and highly-recurrent. Many patients are came in late stage. It is important to identify a prognostic tool that is reliable, easily obtainable, and widely applicable. The aim of this study is to investigate and analyze the prognostic value of clinicopathological and biomarker factors in patients with soft tissue sarcoma. Methods This retrospective study extracts data from the musculoskeletal tumor registry from January 2012 to December 2018 in a single tertiary hospital. Eighty patients with diagnosis of soft tissue sarcoma were included. Preoperative modified Glasgow Prognostic Score, Neutrophils/Lymphocytes Ratio, Hemoglobin, serum lactate dehydrogenase data were analyzed along with demographic, clinical, radiological and histopathological data. The relationship between variables on overall survival, distant metastasis, and local recurrence were evaluated using univariate and multivariate Cox regression. Results On univariate analysis, there was significant relationship between hemoglobin, Neutrophils/Lymphocytes Ratio and modified Glasgow Prognostic Score with overall survival (p = 0.031, HR = 1.99; p = 0.04, HR = 1.129; and p = 0.044, HR = 3.89). A significant relationship was found between age and soft tissue sarcoma stage with distant metastasis (p = 0.046, HR = 1.95; and p = 0.00, HR = 3.22). In addition, we also found significant relationship between surgical margin with local recurrence (p = 0.018, OR = 3.44). However, on multivariate analysis the independent prognostic factor for overall survival was only modified Glasgow Prognostic Score (HR = 2.138; p = 0.011). Stage IIIA (HR = 5.32; p = 0.005) and IIIB (HR = 13.48; p = 0.00) were independent prognostic for distant metastasis. Surgical margin was independently associated with local recurrence (HR = 14.84; p = 0.001). Conclusion Modified Glasgow Prognostic Score can be used as prognostic tool of overall survival in soft tissue sarcoma patients. Moreover, stage of STS and surgical margin can be used as a prognostic factor for distant metastasis and local recurrence of soft tissue sarcoma respectively.

show abstract

Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata

Woll,

Gaunt,

Gaskell

et al. 2023

Br J Cancer

View full text Add to dashboard Cite

Background Axitinib is an oral vascular endothelial growth factor receptor inhibitor with anti-tumour activity in renal, thyroid, and pancreatic cancer. Methods Axi-STS was a pathologically-stratified, non-randomised, open-label, multi-centre, phase II trial of continuous axitinib treatment in patients ≥16 years, performance status ≤2, with pathologically-confirmed advanced/metastatic soft tissue sarcoma (STS). Patients were recruited within four tumour strata, each analysed separately: angiosarcoma, leiomyosarcoma, synovial sarcoma, or other eligible STSs. The primary outcome was progression-free survival at 12 weeks (PFS12). A Simon’s two-stage design with activity defined as PFS12 rate of 40% determined a sample size of 33 patients per strata. Results Between 31-August-2010 and 29-January-2016, 145 patients were recruited: 38 angiosarcoma, 37 leiomyosarcoma, 36 synovial sarcoma, and 34 other subtypes. PFS12 rate for each stratum analysed was 42% (95% lower confidence interval (LCI); 29), 45% (95% LCI; 32), 57% (95% LCI; 42), and 33% (95% LCI; 21), respectively. There were 74 serious adverse events including two treatment-related deaths of pulmonary haemorrhage and gastrointestinal bleeding. Fatigue and hypertension were the most common grade 3 adverse events. Conclusions Axitinib showed clinical activity in all STS strata investigated. The adverse event profile was acceptable, supporting further investigation in phase III trials. Clinical Trial Registration ISRCTN 60791336

show abstract

The modified Glasgow prognostic score in patients undergoing surgery for bone and soft tissue sarcoma

Cited by 16 publications

References 17 publications

The Prognostic Role of Glasgow Prognostic Score and C-reactive Protein to Albumin Ratio for Sarcoma: A System Review and Meta-Analysis

The Prognostic Role of Glasgow Prognostic Score and C-reactive Protein to Albumin Ratio for Sarcoma: A System Review and Meta-Analysis

Analysis of prognostic factors in soft tissue sarcoma: Cancer registry from a single tertiary hospital in Indonesia. A retrospective cohort study

Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata

Contact Info

Product

Resources

About